SE0000597D0 - Novel antibody - Google Patents
Novel antibodyInfo
- Publication number
- SE0000597D0 SE0000597D0 SE0000597A SE0000597A SE0000597D0 SE 0000597 D0 SE0000597 D0 SE 0000597D0 SE 0000597 A SE0000597 A SE 0000597A SE 0000597 A SE0000597 A SE 0000597A SE 0000597 D0 SE0000597 D0 SE 0000597D0
- Authority
- SE
- Sweden
- Prior art keywords
- target
- binds
- substance
- blocks
- tumour cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
YU63702A YU63702A (sh) | 2000-02-24 | 2001-02-23 | Novo antitelo sa specifičnošću za rak debelog creva |
CN01805577A CN1406136A (zh) | 2000-02-24 | 2001-02-23 | 对结肠癌具有特异性的新抗体 |
NZ520523A NZ520523A (en) | 2000-02-24 | 2001-02-23 | A binding structure determined by it heavy chain CDR structures which binds to the cell surface of tumour cells |
SK1198-2002A SK11982002A3 (sk) | 2000-02-24 | 2001-02-23 | Nová protilátka so špecificitou pre rakovinu hrubého čreva |
HU0300007A HUP0300007A3 (en) | 2000-02-24 | 2001-02-23 | Antibody with specificity for colon cancer |
IL15132501A IL151325A0 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
EEP200200473A EE200200473A (et) | 2000-02-24 | 2001-02-23 | Uudne jämesoolevähi-spetsiifiline antikeha |
KR1020027010963A KR20020079888A (ko) | 2000-02-24 | 2001-02-23 | 결장 암에 대해 특이성을 가지는 신규한 항체 |
RU2002125386/15A RU2268068C2 (ru) | 2000-02-24 | 2001-02-23 | Новое антитело со специфичностью к злокачественной опухоли толстой кишки |
EP01908551A EP1257291A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
US10/182,132 US7425623B2 (en) | 2000-02-24 | 2001-02-23 | Antibody with specificity for colon cancer |
AU36294/01A AU775876B2 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
PL01356386A PL356386A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
JP2001561350A JP2003523213A (ja) | 2000-02-24 | 2001-02-23 | 結腸癌に対して特異性を有する新規抗体 |
PCT/SE2001/000395 WO2001062286A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
CA002400661A CA2400661A1 (en) | 2000-02-24 | 2001-02-23 | Novel antibody with specificity for colon cancer |
BR0108609-0A BR0108609A (pt) | 2000-02-24 | 2001-02-23 | Anticorpo com especificidade pelo câncer de cólon |
MXPA02008315A MXPA02008315A (es) | 2000-02-24 | 2001-02-23 | Anticuerpo novedoso con especifidad para cancer de color. |
ZA200206039A ZA200206039B (en) | 2000-02-24 | 2002-07-29 | Novel antibody with specificity for colon cancer. |
NO20023670A NO20023670L (no) | 2000-02-24 | 2002-08-02 | Antistoff med spesifisitet for colonkreft |
HK03104939.3A HK1052648A1 (zh) | 2000-02-24 | 2003-07-09 | 對結腸癌具有特異性的新抗體 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0000597D0 true SE0000597D0 (sv) | 2000-02-24 |
Family
ID=20278567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0000597A SE0000597D0 (sv) | 2000-02-24 | 2000-02-24 | Novel antibody |
Country Status (22)
Country | Link |
---|---|
US (1) | US7425623B2 (pt) |
EP (1) | EP1257291A1 (pt) |
JP (1) | JP2003523213A (pt) |
KR (1) | KR20020079888A (pt) |
CN (1) | CN1406136A (pt) |
AU (1) | AU775876B2 (pt) |
BR (1) | BR0108609A (pt) |
CA (1) | CA2400661A1 (pt) |
EE (1) | EE200200473A (pt) |
HK (1) | HK1052648A1 (pt) |
HU (1) | HUP0300007A3 (pt) |
IL (1) | IL151325A0 (pt) |
MX (1) | MXPA02008315A (pt) |
NO (1) | NO20023670L (pt) |
NZ (1) | NZ520523A (pt) |
PL (1) | PL356386A1 (pt) |
RU (1) | RU2268068C2 (pt) |
SE (1) | SE0000597D0 (pt) |
SK (1) | SK11982002A3 (pt) |
WO (1) | WO2001062286A1 (pt) |
YU (1) | YU63702A (pt) |
ZA (1) | ZA200206039B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2450692A1 (en) * | 2001-06-12 | 2003-01-30 | Kyogo Itoh | Tumor antigen |
US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
CN1303105C (zh) * | 2003-12-08 | 2007-03-07 | 陈志南 | 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用 |
SG172684A1 (en) * | 2006-06-07 | 2011-07-28 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
EP2048241B1 (en) * | 2007-10-08 | 2012-07-25 | Sividon Diagnostics GmbH | Method employing GAPDH as molecular markers for cancer prognosis |
RU2528738C2 (ru) * | 2007-12-18 | 2014-09-20 | Биоэллаенс К.В. | Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения |
JP5515071B2 (ja) * | 2008-09-01 | 2014-06-11 | 国立大学法人名古屋大学 | 抗がん剤の作用増強剤及びその利用、並びにがん患者の予後推定用バイオマーカー及びその利用 |
FR2945952B1 (fr) * | 2009-05-27 | 2013-10-04 | Univ Claude Bernard Lyon | Anticorps anti-ck8 pour utilisation comme medicament. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798257A (en) * | 1990-07-09 | 1998-08-25 | Research Corporation Technologies, Inc. | Nucleic acid encoding human MTS-1 protein |
US5994088A (en) * | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
AU4998993A (en) * | 1992-08-07 | 1994-03-03 | Epimmune, Inc. | Hla binding peptides and their uses |
US5972643A (en) * | 1994-06-17 | 1999-10-26 | Fred Hutchinson Cancer Research Center | Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor |
US6140470A (en) * | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
EP0885299B1 (en) * | 1996-01-08 | 2005-10-26 | Genentech, Inc. | Ob receptor and ligands |
EP0879183A1 (fr) | 1996-07-18 | 1998-11-25 | Montania | Bouchon avec recipient auxiliaire et procede de realisation |
JP2001512560A (ja) * | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
SE9700291D0 (sv) * | 1997-01-31 | 1997-01-31 | Pharmacia & Upjohn Ab | Selection method and prodcts resulting therefrom |
ATE299938T1 (de) * | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
CA2302292A1 (en) * | 1997-08-29 | 1999-03-04 | Selective Genetics, Inc. | Methods using phage display for selecting internalizing ligands for gene delivery |
DE19739525A1 (de) * | 1997-09-09 | 1999-09-30 | Heinrich Abbrederis | Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen |
CA2253633A1 (en) * | 1997-12-03 | 1999-06-03 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
JP2002543044A (ja) * | 1999-03-01 | 2002-12-17 | ジェネンテック・インコーポレーテッド | 癌の治療及び診断のための抗体 |
-
2000
- 2000-02-24 SE SE0000597A patent/SE0000597D0/xx unknown
-
2001
- 2001-02-23 RU RU2002125386/15A patent/RU2268068C2/ru not_active IP Right Cessation
- 2001-02-23 AU AU36294/01A patent/AU775876B2/en not_active Ceased
- 2001-02-23 SK SK1198-2002A patent/SK11982002A3/sk not_active Application Discontinuation
- 2001-02-23 BR BR0108609-0A patent/BR0108609A/pt not_active IP Right Cessation
- 2001-02-23 PL PL01356386A patent/PL356386A1/xx not_active Application Discontinuation
- 2001-02-23 EE EEP200200473A patent/EE200200473A/xx unknown
- 2001-02-23 WO PCT/SE2001/000395 patent/WO2001062286A1/en active IP Right Grant
- 2001-02-23 HU HU0300007A patent/HUP0300007A3/hu unknown
- 2001-02-23 MX MXPA02008315A patent/MXPA02008315A/es unknown
- 2001-02-23 EP EP01908551A patent/EP1257291A1/en not_active Withdrawn
- 2001-02-23 KR KR1020027010963A patent/KR20020079888A/ko not_active Application Discontinuation
- 2001-02-23 IL IL15132501A patent/IL151325A0/xx unknown
- 2001-02-23 YU YU63702A patent/YU63702A/sh unknown
- 2001-02-23 CN CN01805577A patent/CN1406136A/zh active Pending
- 2001-02-23 JP JP2001561350A patent/JP2003523213A/ja not_active Withdrawn
- 2001-02-23 NZ NZ520523A patent/NZ520523A/en unknown
- 2001-02-23 US US10/182,132 patent/US7425623B2/en not_active Expired - Fee Related
- 2001-02-23 CA CA002400661A patent/CA2400661A1/en not_active Abandoned
-
2002
- 2002-07-29 ZA ZA200206039A patent/ZA200206039B/en unknown
- 2002-08-02 NO NO20023670A patent/NO20023670L/no not_active Application Discontinuation
-
2003
- 2003-07-09 HK HK03104939.3A patent/HK1052648A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2268068C2 (ru) | 2006-01-20 |
PL356386A1 (en) | 2004-06-28 |
ZA200206039B (en) | 2003-07-29 |
MXPA02008315A (es) | 2002-12-09 |
JP2003523213A (ja) | 2003-08-05 |
NZ520523A (en) | 2004-08-27 |
NO20023670L (no) | 2002-08-23 |
IL151325A0 (en) | 2003-04-10 |
AU3629401A (en) | 2001-09-03 |
EP1257291A1 (en) | 2002-11-20 |
HUP0300007A3 (en) | 2005-11-28 |
CN1406136A (zh) | 2003-03-26 |
HK1052648A1 (zh) | 2003-09-26 |
US7425623B2 (en) | 2008-09-16 |
HUP0300007A2 (en) | 2003-05-28 |
RU2002125386A (ru) | 2004-03-20 |
US20030176661A1 (en) | 2003-09-18 |
WO2001062286A1 (en) | 2001-08-30 |
NO20023670D0 (no) | 2002-08-02 |
AU775876B2 (en) | 2004-08-19 |
BR0108609A (pt) | 2002-11-19 |
KR20020079888A (ko) | 2002-10-19 |
SK11982002A3 (sk) | 2003-03-04 |
YU63702A (sh) | 2006-01-16 |
EE200200473A (et) | 2004-02-16 |
CA2400661A1 (en) | 2001-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
MXPA05010830A (es) | Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana. | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
TR200103560T2 (tr) | Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı | |
UY26807A1 (es) | Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos | |
WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
NO20055209D0 (no) | Peptabody for cancerbehandling | |
HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
SG158919A1 (en) | Constructs binding to phosphatidylserine and their use in disease treatment | |
ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
EA200501206A1 (ru) | Производные от сурвивина пептиды и их применение | |
TW200604208A (en) | Antibodies to angiogenesis inhibiting domains of CD148 | |
MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. | |
EA201690004A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
MX2009003039A (es) | Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. | |
DK1526840T3 (da) | Nanopartikler til DNA administration til et målorgan | |
WO2005054295A3 (en) | Therapeutic and diagnostic anti-hsp 70 antibodies | |
SE0000597D0 (sv) | Novel antibody | |
WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
CY1113424T1 (el) | Μεθοδος αντιμετωπισης του καρκινου ή/και παθησεις με κυτταρικη υπερπλασια και παραγοντες που στοχευουν τον αναβολισμο υαλουρονανης για τον ιδιο σκοπο | |
WO2008137733A3 (en) | Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents | |
WO2002067771A3 (en) | Chemokine receptors and disease | |
WO2003013431A3 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására |